Our findings and those of other studies confirm that CD4 + T cells likely include tumor antigen-specific subsets, contributing to tumor regression during chemotherapy (Péguillet et al. 2014), highlighting the intricate relationship between immune responses and therapeutic outcomes. This evidence concerns the gene CD4 and neoplasm.